Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 9, 2015-09 ,pp. : 1012-1023

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 58, Iss. 2, 2018-02 ,pp. : 180-192

John Wiley & Sons Inc

Access to resources Recommend Favorite

Recent trends in preclinical drug–drug interaction studies of flavonoids — Review of case studies, issues and perspectives

By  

PHYTOTHERAPY RESEARCH, Vol. 29, Iss. 11, 2015-11 ,pp. : 1679-1691

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hyponatremic Hypervolemia Caused by a Drug–Drug Interaction Mistaken for Syndrome of Inappropriate ADH

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 36, Iss. 3, 1988-03 ,pp. : 285-286

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Novel Design for Drug-Drug Interaction Alerts Improves Prescribing Efficiency

By RussAlissa L.   ChenSiying   MeltonBrittany L.   JohnsonElizabette G.   SpinaJeffrey R.   WeinerMichael   ZillichAlan J.  

Joint Commission Journal on Quality and Patient Safety, Vol. 41, Iss. 9, 2015-09 ,pp. : 396-1AP

Joint Commission Resources

Access to resources Recommend Favorite